Form 4: VolitionRx CSO Micallef's Tax-Related Stock Disposition

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, reported a disposition of 5,850 common shares to satisfy tax withholding obligations related to restricted stock unit settlement.

Summary

• Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd. (VNRX), reported a transaction on October 4, 2025.
• The transaction involved the disposition of 5,850 shares of common stock at a price of $0.648 per share.
• This disposition was for the purpose of satisfying tax withholding obligations upon the settlement of 13,000 restricted stock units.
• No shares were sold by Mr. Micallef or VolitionRx in this transaction; the shares were retained by VolitionRx for cancellation.
• Following this transaction, Mr. Micallef directly beneficially owns 393,089 shares of common stock.
• Indirect beneficial ownership includes 55,000 shares held by his spouse and 38,113 shares held by Borlaug Limited, where Mr. Micallef is a controlling director with voting and dispositive control.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary event related to tax withholding on RSU vesting, which has a neutral impact on company sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This transaction is a routine insider filing, common for executives whose restricted stock units vest. The disposition of shares to cover tax obligations upon vesting is a standard practice and does not typically indicate a change in management's view of the company's prospects or broader industry trends.

Related Party Transactions

• Indirect beneficial ownership includes 55,000 shares held by the reporting person's spouse and 38,113 shares held by Borlaug Limited, a entity where the reporting person is a controlling director with voting and dispositive control.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not reflect a change in the executive's investment thesis or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Keywords

VNRX, VolitionRx, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Jacob Micallef, Chief Scientific Officer, Restricted Stock Units